Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases

Biochemical Pharmacology

Volumn 51, Issue 12, 1996, Pages 1585-1591

  Eizirik, Décio L ^a   Spencer, Peter ^b,c   Kisby, Glen E ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

cycad; cycasin; diabetes mellitus; DNA damage; DNA repair; methylazoxymethanol; N nitrosamines; neurodegenerative diseases; pancreatic islets; streptozotocin

Indexed keywords

ENVIRONMENTAL CHEMICAL; METHYLAZOXYMETHANOL GLUCOSIDE; MUTAGENIC AGENT; NITROSO DERIVATIVE; NITROSOUREA DERIVATIVE; STREPTOZOCIN;

AMYOTROPHIC LATERAL SCLEROSIS; CELL DAMAGE; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; GENOTOXICITY; HUMAN; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS INFECTION;

EID: 0029990691     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02433-6     Document Type: Note

References (92)

1. Hellerström C and Swenne I, Growth pattern of pancreatic islets in mammals. In: Diabetes Pancreas (Eds. Volk BW and Arquilla ER), 2nd Edn, pp. 53-70. Plenum Press, New York, 1985.
2. Mazzarello P, Polini M, Spadari S and Focher F, DNA repair mechanisms in neurological diseases: Facts and hypothesis. J Neuroi Sci 112: 4-14, 1992.
3. Scharfmann R, Tazi A, Polak M, Kanaka C and Czernichow P, Expression of functional nerve growth factor receptors in pancreatic β-cell lines and fetal rat islets in primary culture. Diabetes 42: 1829-1836, 1993.
4. De Camilli P and Jahn R, Pathways to regulated exocytosis in neurons. Annu Rev Physiol 52: 625-645, 1990.
5. + channels and diabetes mellitus. News Physiol Sci 5: 143-147, 1990.
6. Sorenson RL, Garry DG and Brelje TC, Structure and functional considerations of GABA in islets of Langerhans, β-cells and nerves. Diabetes 40: 1365-1374, 1991.
7. Teitelman G, Insulin cells of the pancreas extend neuntes but do not arise from the neuroectoderm. Dev Biol 142: 368-379, 1990.
8. Wallace DC, Diseases of the mitochondrial DNA. Annu Rev Biochem 61: 1175-1212, 1992.
9. Gerbitz K-D, Does the mitochondrial DNA play a role in the pathogenesis of diabetes? Diabetologia 35: 1181-1186, 1992.
10. Koerner DR, Abnormal carbohydrate metabolism in amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam. Diabetes 25: 1055-1065, 1976.
11. Chen K-M and Uebayashi Y, Amyotrophic lateral sclerosis and Parkinson-dementia in Guam: An update. In: Amyotrophic Lateral Sclerosis in Asia and Oceania (Eds. Chen K-M and Yase Y), pp. 199-240. National University, Taiwan, 1984.
12. Spencer PS, Guam ALS/Parkinson-dementia: A long-latency neurotoxic disorder caused by "slow toxin(s)" in food? Can J Neurol Sci 14: 347-357, 1987.
13. Tricker AR and Preussmann R, Carcinogenic N-nitrosamines in the diet: Occurrence, formation, mechanisms and carcinogenic potential. Mutat Res 259: 277-289, 1991.
14. Spencer PS, Kisby GE and Ludolph AC, Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology 41 (Suppl 2): 62-66, 1991.
15. Rossini AA, Greiner DL, Friedman HP and Mordes JP, Immunopathogenesis of diabetes mellitus. Diabetes Rev 1: 43-75, 1993.
16. Dahlquist G, Environmental risk factors in human type 1 diabetes - An epidemiological perspective. Diabetes Metab Rev 11: 37-46, 1995.
17. Dahlquist G, Non-genetic risk determinants of type 1 diabetes. Diabete Metab 20: 251-257, 1994.
18. Yoon J-W, A new look at viruses in type 1 diabetes. Diabetes Metab Rev 11: 83-107, 1995.
19. Helgason T and Jonason MR, Evidence for food additive as a cause of ketosis-prone diabetes. Lancet II: 716-720, 1981.
20. Helgason T, Ewen SWB, Ross IS and Stowers JM, Diabetes produced in mice by smoked/cured mutton. Lancet II: 1017-1022, 1982.
21. Dahlquist G, Blom L, Persson LÅ, Sandström A and Wall S, Dietary factors and the risk of developing insulin-dependent diabetes mellitus in childhood. Br Med J 300: 1302-1306, 1990.
22. Kostraba JN, Gay EC, Rewers M and Hamman RF, Nitrate levels in community drinking waters and risk of IDDM. Diabetes Care 15: 1505-1508, 1992.
23. Boucher BJ, Ewen SWB and Stowers JM, Betel nut (Areca catechu) consumption and the induction of glucose intolerance in adult CD1 mice and in their F1 and F2 offspring. Diabetologia 37: 49-55, 1994.
24. Eizirik DL and Kisby GE, Cycad toxin-induced damage of rodent and human pancreatic β-cells. Biochem Pharmacol 50: 355-365, 1995.
25. Wilson GL and Leiter EH, Streptozotocin interactions with pancreatic β-cells and the induction of diabetes. Curr Top Microbiol Immunol 156: 27-54, 1990.
26. Wilson GL and LeDoux SP, Interactions of chemicals with pancreatic β-cells. In: Lessons from Animal Diabetes IV (Ed. Shafrir E), pp. 17-26. Smith-Gordon, London, 1993.
27. Like AA and Rossini AA, Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus. Science 193: 415-417, 1976.
28. Kolb H and Kröncke K-D, IDDM - Lessons from the low-dose streptozotocin model in mice. Diabetes Rev 1: 116-126, 1993.
29. Mayer G, Nitsch R and Hoyer S, Effects of changes to peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats. Brain Res 532: 95-100, 1990.
30. Plaschke K and Hoyer S, Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism of adult brain cortex and hippocampus. Int J Dev Neurosci 11: 477-483, 1993.
31. Ding A, Nitsch R and Hoyer S, Changes in brain monoaminergic neurotransmitter concentrations in rat after intracerebroventricular injection of streptozotocin. J Cereb Blood Flow Metab 12: 103-109, 1992.
32. Hellweg R, Nitsch R, Hock C, Jaksch M and Hoyder S, Nerve growth factor and choline acetyltransferase activity levels in the rat brain following experimental impairment of cerebral glucose and energy metabolism. J Neurosci Res 31: 479-486, 1992.
33. Blokland A and Jolles J, Behavioral and biochemical effects of an ICV injection of streptozotocin in old Lewis rats. Pharmacol Biochem Behav 47: 833-837, 1994.
34. Prickaerts J, Blokland A, Honing W, Meng F and Jolles J, Spatial discrimination learning and choline acetyltransferase activity in streptozotocin-treated rats: Effects of chronic treatment with acetyl-L-carnitine. Brain Res 674: 142-146, 1995.
35. Nitsch R, Mayer G and Hoyer S, The intracerebroventricular streptozotocin-treated rat: Impairment of cerebral glucose metabolism of the brain in Alzheimer's disease. J Neural Transm 1: 109-110, 1989.
36. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM and Kopin IJ, Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249-254, 1979.
37. Garruto RM and Yase Y, Neurodegenerative disorders of the western Pacific: The search for mechanisms of pathogenesis. Trends Neurosci 9: 368-375, 1986.
38. Garruto RM, Yanagihara R and Gajdusek DC, Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology 35: 193-198, 1985.
39. Spencer PS, Palmer VS, Herman A and Asmedi A. Cycad use and motor neurone disease in Irian Jaya. Lancet 2: 1273-1274, 1987.
40. Spencer PS, Ohta M and Palmer VS, Cycad use and motor neurone disease in Ku peninsula of Japan. Lancet 2: 1462-1463, 1987.
41. Gibbs CJ Jr and Gajdusek DC, An update on long-term in vivo and in vitro studies designed to identify a virus as the cause of amyotrophic lateral sclerosis, Parkinsonism dementia, and Parkinson's disease. In: Human Motor Neuron Diseases (Ed. Rowland LP), pp. 343-354. Raven Press, New York, 1982.
42. Kurland LT and Molgaard CA, Guamanian ALS: Hereditary or acquired? In: Human Motor Neuron Diseases (Ed. Rowland LP), pp. 165-172. Raven Press, New York, 1982.
43. Spencer PS, Allen CA, Kisby GE and Ludolph AC, On the etiology and pathogenesis of chemically induced neurodegenerative disorders. Neurobiol Aging 15: 265-267, 1994.
44. Ahlskog JE, Waring SC, Kurland LT, Petersen RC, Moyer TP, Harmsen WS, Maragonore DM, O'Brien PC, Estebanantillan C and Bush V, Guamanian neurodegenerative disease: Investigations of the calcium metabolism/heavy metal hypothesis. Neurology 45: 1340-1344, 1995.
45. Reed D, Labarthe D, Chen KM and Stallones R, A cohort study of amyotrophic lateral sclerosis and Parkinson-dementia on Guam and Rota. Am J Epidemiol 125: 92-100, 1987.
46. Spencer PS, Ross SM, Kisby G and Roy DN, Western Pacific amyotrophic lateral sclerosis: Putative role of cycad toxins. In: Amyotrophic Lateral Sclerosis: Concepts in Pathogenesis and Etiology (Ed. Hudson AJ), pp. 263-295. University of Toronto Press, Toronto, 1990.
47. Kobayashi A, Cycasin in cycad materials used in Japan. Fed Proc 31: 1476-1477, 1972.
48. Eizink DL, Sandler S, Welsh N and Hellerström C, Preferential reduction of insulin production in mouse pancreatic islets maintained in culture after streptozotocin exposure. Endocrinology 122: 1242-1249, 1988.
49. Strandell E, Eizirik DL, Korsgren O and Sandler S, Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations. Mol Cell Endocrinol 59: 83-91, 1988.
50. Eizirik DL, Sandler S, Sener A and Malaisse WJ, Defective catabolism of D-glucose and L-glutamine in mouse pancreatic islets maintained in culture after streptozotocin exposure. Endocrinology 123: 1001-1007, 1988.
51. Eizirik DL, Sandler S, Korsgren O, Jansson L and Andersson A, Persistent impairment of the insulin response to glucose both in vivo and in vitro after streptozotocin exposure: Studies with grafted pancreatic islets and islets maintained in culture. Acta Endocrinol (Copenh) 121: 849-856, 1989.
52. Inoue K, Cetkovic-Cvrlje M, Eizirik DL and Grill V, Irreversible loss of normal beta-cell regulation by glucose in neonatally streptozotocin diabetic rats. Diabetologia 37: 351-357, 1994.
53. Eizirik DL and Sandler S, Functional restoration of cultured mouse pancreatic islets after in vitro exposure to alloxan. Pharmacol Toxicol 63: 396-399, 1988.
54. Eizirik DL, Strandell E, Bendtzen K and Sandler S, Functional characteristics of rat pancreatic islets maintained in culture after exposure to human interleukin-1. Diabetes 37: 916-919, 1988.
55. Welsh M, Eizirik DL and Strandell E, Heat shock treatment of mouse pancreatic islets results in a partial loss of islet cells but no remaining functional impairment among the surviving β-cells. J Mol Endocrinol 1: 27-31, 1988.
56. Svensson C, Welsh N, Krawetz S and Welsh M, Exhibition of specific alterations in activities and mRNA levels of rat islet glycolytic and mitochondrial enzymes in three different in vitro model systems for attenuated insulin release. Diabetes 40: 771-776, 1991.
57. Moreira JE, Hand AR, Borg LAH, Sandler S, Welsh M, Welsh N and Eizirik DL, Decrease of insulin-containing secretory granules and mitochondrial gene expression in mouse pancreatic islets maintained in culture following streptozotocin exposure. Virchows Arch B 60: 337-344, 1991.
58. Eizirik DL, Sandler S, Ahnström G and Welsh M, Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of β-cells. Biochem Pharmacol 42: 2275-2282, 1991.
59. Welsh N, Pääbo S and Welsh M, Decreased mitochondrial gene expression in isolated islets of rats injected neonatally with streptozotocin. Diabetologia 34: 626-631, 1991.
60. Rasschaert J, Eizirik DL and Malaisse WJ, Long term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic islets. Endocrinology 130: 3522-3528, 1992.
61. Malaisse WJ, Glucose-sensing by the pancreatic B-cell: The mitochondrial part. Int J Biochem 24: 693-701, 1992.
62. LeDoux SP, Hall CR, Forbes PM, Patton NJ and Wilson GL, Mechanisms of nicotinamide protection from alloxan and streptozotocin toxicity. Diabetes 37: 1015-1019, 1988.
63. Schnedl WJ, Ferber S, Johnson JH and Newgard CB, STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43: 1326-1333, 1994.
64. Bennet RA and Pegg AE, Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res 41: 2786-2790, 1981.
65. LeDoux SP, Woodley SE, Patton NJ and Wilson GL, Mechanisms of nitrosourea-induced B-cell damage. Alterations in DNA. Diabetes 35: 866-872, 1986.
66. Yamamoto H, Uchigata Y and Okamoto H, Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294: 284-286, 1981.
67. Anisimov VN, Effect of aging and interval between primary and secondary treatment in carcinogenesis induced by neonatal exposure to 5-bromodeoxyuridine and subsequent administration of N-nitrosomethylurea in rats. Mutat Res 316: 173-187, 1995.
68. Kisby GE, Sweatt C, McEvoy S and Spencer PS, Potentiation of cycad toxin-induced DNA damage in brain tissue by DNA repair inhibitors. Soc Neurosci Abstr 20: 1649, 1994.
69. 6-methylguanine in human cell killing, sister chromatid exchange induction and mutagenesis: A review. J Cell Sci 6 (Suppl): 333-353, 1987.
70. 6-methylguanine in rat pancreatic β-cells after exposure to N-methyl-N-nitrosourea. Diabetes 42: 1187-1194, 1993.
71. Kisby GE, Sweatt C and Spencer PS, Role of DNA repair in protecting mature nervous tissue from DNA damage. J Cell Biochem 21A (Suppl): 348, 1995.
72. Esclaire F, Kisby GE, Sindou P, Lesort M, Sweatt C, Spencer P and Hugon J, The cycad toxin MAM enhances neuronal tau mRNA expression produced by glutamate. J Cell Biochem 21B: 97, 1995.
73. Turk J, Corbett JA, Ramanadham S, Bohrer A and McDaniel ML, Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun 197: 1458-1464, 1993.
74. Kwon NS, Lee SH, Choi CS, Kho T and Lee HS, Nitric oxide generation from streptozotocin. FASEB J 8: 529-533, 1994.
75. Kröncke K-D, Fehsel K, Sommer A, Rodriguez M-L and Kolb-Bachofen V, Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotocin contributes to islet cell DNA damage. Biol Chem Hoppe Seyler 376: 179-185, 1995.
76. Kröncke K-D, Brenner HH, Rodriguez ML, Etzkorn K, Noack EA, Kolb H and Kolb-Bachofen V, Pancreatic islet cells are highly susceptible towards the cytotoxic effects of chemically generated nitric oxide. Biochim Biophys Acta 1182: 221-229, 1993.
77. Ohshima H, Tsuda M, Adashi H, Ogura T, Sugimura T and Esumi H, L-Arginine-dependent formation of N-nitrosamines by the cytosol of macrophages activated with lipopolysaccharide and interferon-γ. Carcinogenesis 12: 1217-1220, 1991.
78. Corbett JA and McDaniel ML, Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 41: 897-903, 1992.
79. Kolb H and Kolb-Bachofen V, Type 1 (insulin-dependent) diabetes mellitus and nitric oxide. Diabetologia 35: 796-797, 1992.
80. Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerström C and Andersson A, Major species differences between humans and rodents in the susceptibility to pancreatic β-cell injury. Proc Natl Acad Sci USA 91: 9253-9256, 1994.
81. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K and Hellerström C, Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest 93: 1968-1974, 1994.
82. Kato H, Harada M, Tsuchiya K and Moriwaki K, Absence of correlation between DNA repair in ultraviolet irradiated mammalian cells and life span of the donor species. Jpn J Genet 55: 99-108, 1980.
83. Welsh N, Margulis B, Borg H, Jernberg-Wiklund H, Saldeen J, Flodström M, Mello MA, Andersson A, Pipeleers DG, Hellerström C and Eizirik DL, Differential expression of heatshock proteins and antioxidant enzymes in isolated human and rodent pancreatic islets. Implications for pathogenesis of insulin-dependent diabetes mellitus. Mol Med 1: 806-820, 1995.
84. Margulis BA, Sandler S, Eizirik DL, Welsh N and Welsh M, Liposomal delivery of purified heat shock protein hsp70 into rat pancreatic islets as protection against interleukin 1β-induced impaired β-cell function. Diabetes 40: 1418-1422, 1991.
85. Bellman K, Wenz A, Radons J, Burkart V, Kleemann R and KoIb H, Heat shock induces resistance in rat pancreatic islets against nitric oxide, oxygen radicals and streptozotocin toxicity in vitro. J Clin Invest 95: 2840-2845, 1995.
86. Eizirik DL, Sandler S and Palmer J, Repair of pancreatic β-cells. A relevant phenomenon in early IDDM? Diabetes 42: 1383-1391, 1993.
87. Harris CC, Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 10: 1563-1566, 1989.
88. Karvonen M, Tuomilehto J, Libman I and LaPorte R, A review of the recent epidemiological data on the worldwide incidence of Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36: 883-892, 1993.
89. Berne C, Gunnarsson R, Hellerström C and Wilander E, Diabetogenic nitrosamines? Lancet I: 173-174, 1974.
90. Harlan DM, Barnett MA, Abe R, Pechhold K, Patterson NB, Gray GS and June CH, Very-low dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. Diabetes 44: 816-823, 1995.
91. Kohnert K-D, Odselius R, Fält K, Ziegler B, Ziegler M and Falkmer S, Destruction of pancreatic beta cells in rats by complete Freund's adjuvant combined with non-diabetogenic doses of streptozotocin. Diabetes Res 5: 1-11, 1987.
92. Beck MA, Shi Q, Morris VC and Levander OA, Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nature Med 1: 433-436, 1995.